Alligator Bioscience Successfully Completes End of Phase 2 Interaction with FDA For Mitazalimab
FDA feedback validates the clinical development strategy and Phase 3 design FDA feedback confirms that the toxicology package is adequate fo ...
Change in number of shares and votes in Alligator Bioscience
During the month of January, the number of shares and votes in Alligator Bioscience AB has changed as a result of the exercise of warrants s ...
Alligator Bioscience Announces Publication of Clinical Data for ATOR-1017 (evunzekibart) in the Journal for ImmunoTherapy of Cancer
Publication validates encouraging clinical safety and tolerability in this first-in-human trial Data show early signs of clinical efficacy i ...
The subscription period in Alligator Bioscience’s rights issue begins today
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience Reports Incremental Overall Survival Benefit of mitazalimab combined with mFOLFIRINOX based on Literature-based Indirect Comparison of Outcomes
Indirect Comparison shows significant improvement of OS of mitazalimab + mFOLFIRINOX, compared to known FOLFIRINOX and NALIRIFOX outcomes Th ...
Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience AB reports full year financial results for 2024 and for Q4 2024 and provides a business update
Sharpened focus on mitazalimab and cost-reduction program to maximize long-term value creation Announcement of rights issue of units of appr ...
Alligator Bioscience announces final terms of rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience Announces Positive Outcome of Regulatory Interactions on Phase 3 CMC activities
FDA feedback reinforces manufacturing strategy reducing regulatory risk of the program Feedback confirms completed and planned CMC-work as P ...